ES3024479T3 - Managing nephrogenic diabetes insipidus - Google Patents
Managing nephrogenic diabetes insipidus Download PDFInfo
- Publication number
- ES3024479T3 ES3024479T3 ES18748236T ES18748236T ES3024479T3 ES 3024479 T3 ES3024479 T3 ES 3024479T3 ES 18748236 T ES18748236 T ES 18748236T ES 18748236 T ES18748236 T ES 18748236T ES 3024479 T3 ES3024479 T3 ES 3024479T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- individual
- pharmaceutically acceptable
- stereoisomers
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452616P | 2017-01-31 | 2017-01-31 | |
| PCT/US2018/016184 WO2018144570A1 (fr) | 2017-01-31 | 2018-01-31 | Gestion du diabète insipide néphrogène |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3024479T3 true ES3024479T3 (en) | 2025-06-04 |
Family
ID=63040033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18748236T Active ES3024479T3 (en) | 2017-01-31 | 2018-01-31 | Managing nephrogenic diabetes insipidus |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11179354B2 (fr) |
| EP (1) | EP3618821B8 (fr) |
| AU (1) | AU2018217038B2 (fr) |
| CA (1) | CA3071385A1 (fr) |
| DK (1) | DK3618821T3 (fr) |
| ES (1) | ES3024479T3 (fr) |
| FI (1) | FI3618821T3 (fr) |
| HR (1) | HRP20250377T1 (fr) |
| HU (1) | HUE071486T2 (fr) |
| LT (1) | LT3618821T (fr) |
| PL (1) | PL3618821T3 (fr) |
| PT (1) | PT3618821T (fr) |
| SI (1) | SI3618821T1 (fr) |
| WO (1) | WO2018144570A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9827222B2 (en) | 2013-07-01 | 2017-11-28 | Emory University | Treating or preventing nephrogenic diabetes insipidus |
| EP3618821B8 (fr) | 2017-01-31 | 2025-04-23 | NephroDI Therapeutics, Inc. | Gestion du diabète insipide néphrogène |
| US20230364039A1 (en) * | 2020-10-14 | 2023-11-16 | Emory University | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5864381A (en) | 1996-07-10 | 1999-01-26 | Sandia Corporation | Automated pupil remapping with binary optics |
| US7335689B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
| WO2006060079A2 (fr) * | 2004-10-25 | 2006-06-08 | University Of Utah Research Foundation | Methodes et compostions de traitement du diabete insipide nephrogenique |
| CN103327974A (zh) | 2010-09-20 | 2013-09-25 | 卡留斯治疗公司 | 用于治疗糖尿病和血脂异常的方法和组合物 |
| US20140121267A1 (en) | 2011-09-20 | 2014-05-01 | Kareus Therapeutics, Sa | Methods and compositions for treatment of diabetes and dyslipidemia |
| US9827222B2 (en) | 2013-07-01 | 2017-11-28 | Emory University | Treating or preventing nephrogenic diabetes insipidus |
| WO2015101609A1 (fr) | 2013-12-31 | 2015-07-09 | Stichting Katholieke Universiteit | Méthode de traitement d'affections rénales |
| EP3618821B8 (fr) | 2017-01-31 | 2025-04-23 | NephroDI Therapeutics, Inc. | Gestion du diabète insipide néphrogène |
-
2018
- 2018-01-31 EP EP18748236.9A patent/EP3618821B8/fr active Active
- 2018-01-31 ES ES18748236T patent/ES3024479T3/es active Active
- 2018-01-31 CA CA3071385A patent/CA3071385A1/fr active Pending
- 2018-01-31 PL PL18748236.9T patent/PL3618821T3/pl unknown
- 2018-01-31 SI SI201831225T patent/SI3618821T1/sl unknown
- 2018-01-31 DK DK18748236.9T patent/DK3618821T3/da active
- 2018-01-31 US US16/491,990 patent/US11179354B2/en active Active
- 2018-01-31 PT PT187482369T patent/PT3618821T/pt unknown
- 2018-01-31 AU AU2018217038A patent/AU2018217038B2/en active Active
- 2018-01-31 FI FIEP18748236.9T patent/FI3618821T3/fi active
- 2018-01-31 HR HRP20250377TT patent/HRP20250377T1/hr unknown
- 2018-01-31 LT LTEPPCT/US2018/016184T patent/LT3618821T/lt unknown
- 2018-01-31 HU HUE18748236A patent/HUE071486T2/hu unknown
- 2018-01-31 WO PCT/US2018/016184 patent/WO2018144570A1/fr not_active Ceased
-
2021
- 2021-10-20 US US17/506,236 patent/US11844770B2/en active Active
-
2023
- 2023-11-06 US US18/502,729 patent/US12433858B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240139127A1 (en) | 2024-05-02 |
| HRP20250377T1 (hr) | 2025-07-18 |
| PT3618821T (pt) | 2025-05-14 |
| US20220031639A1 (en) | 2022-02-03 |
| LT3618821T (lt) | 2025-05-26 |
| AU2018217038A1 (en) | 2020-07-02 |
| CA3071385A1 (fr) | 2018-08-09 |
| US11844770B2 (en) | 2023-12-19 |
| WO2018144570A1 (fr) | 2018-08-09 |
| EP3618821B1 (fr) | 2025-03-12 |
| EP3618821A4 (fr) | 2021-03-03 |
| PL3618821T3 (pl) | 2025-07-07 |
| SI3618821T1 (sl) | 2025-07-31 |
| EP3618821B8 (fr) | 2025-04-23 |
| EP3618821A1 (fr) | 2020-03-11 |
| AU2018217038B2 (en) | 2023-07-06 |
| US11179354B2 (en) | 2021-11-23 |
| US12433858B2 (en) | 2025-10-07 |
| DK3618821T3 (da) | 2025-04-07 |
| HUE071486T2 (hu) | 2025-09-28 |
| US20200383940A1 (en) | 2020-12-10 |
| FI3618821T3 (fi) | 2025-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12433858B2 (en) | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | |
| ES2911207T3 (es) | Composiciones de insulina de acción rápida | |
| ES2702848T3 (es) | Complejos de flumazenil, composiciones que los comprenden y usos de los mismos | |
| ES2683902T3 (es) | Administración de benzodiacepina | |
| ES2507491T3 (es) | Preparación farmacéutica que comprende un inhibidor de DPP-IV y otros agentes terapéuticos de la diabetes en forma concomitante o combinada | |
| ES2627944T3 (es) | Composiciones y métodos de tratamiento de hipertensión pulmonar | |
| TWI763632B (zh) | 用於重症治療時之鎮靜方法及非口服調配物 | |
| ES2779006T3 (es) | Composiciones de DNJ parenterales estables | |
| JP2020520963A (ja) | 抑うつ障害の処置 | |
| ES2383433T3 (es) | Formulación farmacéutica de apomorfina para administración bucal | |
| ES2903136T3 (es) | Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington | |
| ES2399569T3 (es) | Composición farmacéutica líquida estable a base de trazodona | |
| ES2358931T3 (es) | Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos. | |
| EP1543826A1 (fr) | Solution aqueous concentree de ambroxol | |
| ES2239042T3 (es) | Nueva combinacion para el tratamiento de la disfuncion sexual. | |
| ES2634026T3 (es) | Composiciones medicinales | |
| ES2617235T3 (es) | Uso de pidotimod para tratar psoriasis | |
| ES2370790A1 (es) | Uso de oxalacetato en el tratamiento de isquemia. | |
| ES2247060T3 (es) | Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial. | |
| WO2016024369A1 (fr) | Composition médicinale pour le traitement du cancer | |
| ES2992016T3 (es) | Una solución acuosa estable de hidroxicarbamida | |
| WO2012049550A1 (fr) | Composition pharmaceutique liquide pour le traitement et la prévention de la douleur | |
| ES2761311T3 (es) | Tratamiento terapéutico | |
| ES2754449T3 (es) | Acido carboxílico de pirrolidona (pca) para uso oftálmico | |
| EP4518848A1 (fr) | Baclofène intranasal |